The endocannabinoid system (ECS) and its interaction with the immune system have been the subject of extensive research in recent years. The ECS is a complex signaling system involved in various physiological processes, including immune function, inflammation, and neuroprotection. It consists of endocannabinoids, which are naturally produced by the body, enzymes, and cannabinoid receptors, expressed in various cell types, including immune cells.

Cannabinoid receptors, specifically CB1 and CB2 receptors, play a significant role in the modulation of the immune response in autoimmune diseases. In short, the activation of CB2 receptors has been shown to have immunomodulatory effects, including the inhibition of pro-inflammatory cytokine production, the modulation of immune cell function, and the regulation of inflammation. On the other hand, the activation of CB1 receptors has been shown to have anti-inflammatory and neuroprotective effects in autoimmune diseases.

Here are some relevant research findings: 

Regulation of Immune Response: CB2 receptors primarily regulate immune response, inhibiting pro-inflammatory mediators and immune cell proliferation. CB1 receptors play a role in regulating inflammation and neuroprotection in autoimmune diseases.

Modulation of Microglial Antigen Generation: CB1 and CB2 receptors modulate antigen generation in microglial cells, impacting autoimmune responses in the central nervous system.

Neuroprotection in Autoimmune Diseases: CB1 receptors mediate neuroprotection, reducing disease severity in autoimmune conditions like experimental autoimmune encephalomyelitis (EAE).

Control of CNS Innate Immunity: Cannabinoid receptors, including CB1 and CB2, affect CNS innate immunity, offering potential therapeutic avenues for autoimmune and neuroinflammatory conditions.

Role in Pediatric Inflammatory and Immune Diseases: the endocannabinoid system, including cannabinoid receptors, is implicated in pediatric inflammatory and autoimmune diseases, offering insights into diagnostic markers and therapeutic targets.

While more research is needed, studies indicate cannabinoids can downregulate the immune response by modulating the endocannabinoid system. This modulation is relevant for the treatment of prevalent autoimmune diseases. In multiple sclerosis, cannabinoids like CBD and THC have been shown to alleviate symptoms of pain and spasticity, while CBG and CBC are also being studied. In animal studies, CBD has been shown to have anti-inflammatory properties and reduce the amounts of T-cell infiltrates in the spinal cord.  In Rheumatoid arthritis, CB2 receptor activation has been proposed as a possible target for treating RA and other inflammatory and autoimmune diseases related to immune cell activation. Animal studies have suggested that CBD, CBG, and THC, in different combinations, could consistently reduce pro-inflammatory cytokines and decrease inflammation and pain. Activation of the cannabinoid receptors, especially CB2, is also known for its immunosuppressive roles in Type 1 diabetes mellitus, Crohn’s, celiac disease, Inflammatory bowel disease, Lupus, and neuroinflammatory diseases.

Phytocannabinoids, such as THC, CBD, CBG, and CBN, have been shown to modulate immune function by activating cannabinoid receptors, particularly CB2 receptors. They may modulate cytokine production, regulate inflammation, modulate immune cell function, and have antitumor effects.  

Some of the research findings involving the action of phytocannabinoids:

Delta-9-tetrahydrocannabinol (THC): Exhibits immunosuppressive effects by inhibiting T and B cell proliferation and reducing cytokine production.

Cannabidiol (CBD): Has immunomodulatory effects, including anti-inflammatory actions and enhanced immune cell activity.

Cannabigerol (CBG): Modulates cytokine production and enhances immune cell function, particularly T cells and natural killer cells.

Cannabinol (CBN): Exhibits immunomodulatory effects, reducing inflammation and modulating cytokine production.

In addition to their effects on the immune system, phytocannabinoids have been shown to have various other therapeutic properties relevant to autoimmune patients. For example, THC has been shown to have analgesic, antiemetic, and appetite-stimulating effects, while CBD has been shown to have anxiolytic and antidepressant effects and to help enhance REM sleep.

That being said, the use of phytocannabinoids has the potential to not only treat autoimmune diseases but also improve other issues arising from living with an autoimmune disease that significantly impacts quality of life. While the precise mechanisms are not fully understood, recent research findings and several anecdotal patient reports underscore the potential of phytocannabinoids in immune-related therapeutic applications.

References

• Argenziano, M., Tortora, C., Bellini, G., Di Paola, A., Punzo, F., & Rossi, F. (2019). The Endocannabinoid System in Pediatric Inflammatory and Immune Diseases. International Journal of Molecular Sciences, 20(23), 5875. doi:10.3390/ijms20235875.
• Aziz, A. I., Nguyen, L. C., Oumeslakht, L., Bensussan, A., & Ben Mkaddem, S. (2023). Cannabinoids as Immune System Modulators: Cannabidiol Potential Therapeutic Approaches and Limitations. Cannabis and Cannabinoid Research, 8(2), 254-269. doi:10.1089/can.2022.0133.
• Cankara, F. N., Çelik, Z. B., & Günaydın, C. (2021). Cannabinoid receptors modulate LPS-induced increase of class-II transactivator expression levels in a microglial cell line. Journal of Receptor and Signal Transduction Research, 41(3), 209-216. doi:10.1080/10799893.2020.1868510.
• Giorgi, V., Marotto, D., Batticciotto, A., Atzeni, F., Bongiovanni, S., & Sarzi-Puttini, P. (2021). Cannabis and Autoimmunity: Possible Mechanisms of Action. Immunotargets and Therapy, 10, 261-271. doi:10.2147/ITT.S267905.
• Hernangómez, M., Carrillo-Salinas, F. J., Mecha, M., Correa, F., Mestre, L., Loría, F., … Guaza, C. (2014). Brain innate immunity in the regulation of neuroinflammation: therapeutic strategies by modulating CD200-CD200R interaction involve the cannabinoid system. Current Pharmaceutical Design, 20(29), 4707-4722. doi:10.2174/1381612820666140130202911.
• James Matthew Nichols, & Barbara Kaplan. (2019). The role of CB1 in experimental autoimmune encephalomyelitis (EAE). Journal of Immunology, 202(1_Supplement), 180.12. https://doi.org/10.4049/jimmunol.202.Supp.180.12.
• Jones É, Vlachou S. A Critical Review of the Role of the Cannabinoid Compounds Δ9-Tetrahydrocannabinol (Δ9-THC) and Cannabidiol (CBD) and their Combination in Multiple Sclerosis Treatment. Molecules. 2020 Oct 25;25(21):4930. doi: 10.3390/molecules25214930. PMID: 33113776; PMCID: PMC7663366.
• Katchan, V., David, P., & Shoenfeld, Y. (2016). Cannabinoids and autoimmune diseases: A systematic review. Autoimmunity Reviews, 15(6), 513-528. https://doi.org/10.1016/j.autrev.2016.02.008.
• Kotschenreuther, K., Waqué, I., Yan, S., Meyer, A., Haak, T., von Tresckow, J., … Kofler, D. M. (2021). Cannabinoids drive Th17 cell differentiation in patients with rheumatic autoimmune diseases. Cellular and Molecular Immunology, 18(3), 764-766. doi:10.1038/s41423-020-0437-4.
• Lowin, T., Schneider, M., & Pongratz, G. (2019). Joints for joints: cannabinoids in the treatment of rheumatoid arthritis. Current Opinion in Rheumatology, 31(3), 271-278. doi:10.1097/BOR.0000000000000590.
• Liu, Q. R., Aseer, K. R., Yao, Q., Zhong, X., Ghosh, P., O’Connell, J. F., & Egan, J. M. (2022). Anti-Inflammatory and Pro-Autophagy Effects of the Cannabinoid Receptor CB2R: Possibility of Modulation in Type 1 Diabetes. Frontiers in Pharmacology, 12, 809965. doi:10.3389/fphar.2021.809965.
• Oláh, A., Szekanecz, Z., & Bíró, T. (2017). Targeting Cannabinoid Signaling in the Immune System: “High”-ly Exciting Questions, Possibilities, and Challenges. Frontiers in Immunology, 8, 1487. doi:10.3389/fimmu.2017.01487.
• Pénzes Z, Alimohammadi S, Horváth D, Oláh A, Tóth BI, Bácsi A, Szöllősi AG. The dual role of cannabidiol on monocyte-derived dendritic cell differentiation and maturation. Front Immunol. 2023 Aug 22;14:1240800. doi: 10.3389/fimmu.2023.1240800. PMID: 37680639; PMCID: PMC10482398.
• Rodríguez Mesa, X. M., Moreno Vergara, A. F., Contreras Bolaños, L. A., Guevara Moriones, N., Mejía Piñeros, A. L., & Santander González, S. P. (2021). Therapeutic Prospects of Cannabinoids in the Immunomodulation of Prevalent Autoimmune Diseases. Cannabis and Cannabinoid Research, 6(3), 196-210. doi:10.1089/can.2020.0183.
• Yekhtin, Z., Khuja, I., Meiri, D., Or, R., & Almogi-Hazan, O. (2022). Differential Effects of D9 Tetrahydrocannabinol (THC)- and Cannabidiol (CBD)-Based Cannabinoid Treatments on Macrophage Immune Function In Vitro and on Gastrointestinal Inflammation in a Murine Model. Biomedicines, 10(8), 1793. doi:10.3390/biomedicines10081793.